<DOC>
	<DOCNO>NCT00667355</DOCNO>
	<brief_summary>To evaluate efficacy , safety pharmacokinetics adalimumab Japanese subject active ankylose spondylitis</brief_summary>
	<brief_title>A Study Adalimumab Japanese Subjects With Active Ankylosing Spondylitis</brief_title>
	<detailed_description>It report prevalence Ankylosing Spondylitis ( AS ) Japanese patient extremely low Caucasians ; therefore , control , double-blind study similar sample size Western study active AS Japan able conduct . As result , study conduct open-label design investigate efficacy , safety pharmacokinetics adalimumab Japanese subject active AS . The inclusion criterion primary endpoint measurement ( Achieving Assessment Ankylosing Spondylitis 20 Week 12 ) design Western study active AS consideration confirmation Western data . Treatment adalimumab continue approval adalimumab AS Japanese subject active AS .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject meet definition Ankylosing Spondylitis base Modified New York Criteria , diagnosis active Ankylosing Spondylitis inadequate response intolerance one nonsteroidal antiinflammatory drug History cancer , lymphoma , leukemia lymphoproliferative disease , active TB , HIV Previously receive antiTNF therapy Spinal surgery joint surgery involve joint assess within 2 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>